

Galustian, C., Meyer, B., Labarthe, M. C., Dredge, K., Klaschka, D., Henry, J., ... & Dalglish, A. G. (2009). The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. *Cancer Immunology, Immunotherapy*, 58(7), 1033-1045.

Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., ... & Bromberg, J. F. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. *Journal of Clinical Investigation*, 117(12), 3846-3856.

Gasteiger, J., & Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. *Tetrahedron*, 36(22), 3219-3228.

Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., ... & Erlichman, C. (2005). Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. *Journal of Clinical Oncology*, 23(6), 1078-1087.

Grem, J. L., Morrison, G., Guo, X. D., Agnew, E., Takimoto, C. H., Thomas, R., ... & Wilson, R. H. (2005). Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. *Journal of Clinical Oncology*, 23(9), 1885-1893.

Guichard, M., Stern, S., Lartigau, E. (1998). Radiorésistance liée à l'hypoxie : de la cellule à l'homme. *Journal of Chemical Physics*, 95(4), 782-787.

Hamano, Y., & Kalluri, R. (2005). Tumstatin, the NC1 domain of $\alpha 3$ chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. *Biochemical and biophysical research communications*, 333(2), 292-298.